Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2

Runqiang Chen¹ , Hui Xie¹ , Sahba Khorsandzadeh^1,2 , Madison Smith^1,2 , Namir Shaabani¹ , Qidong Hu¹ , Xiaoxuan Lyu¹ , Hua Wang¹ , Wan-lin Lim¹ , Haotian Sun¹ , Henry Ji¹ , Brian Cooley^1,2 , Russell Ross^1,2 , David M. Francis^1,2,*

¹Sorrento Therapeutics, Inc., San Diego, CA 92121, USA
²Sofusa, a Division of Sorrento Therapeutics, Atlanta, GA 30350, USA
^*Correspondence to:David M. Francis , Email:dfrancis@sorrentotherapeutics.com

J Mol Cell Biol, Volume 14, Issue 6, June 2022, mjac041,  https://doi.org/10.1093/jmcb/mjac041

Keyword: COVID-19, lymph nodes, lymphatics, vaccines, drug delivery

• Abstract
• Full Text

---